-
公开(公告)号：US20180265930A1
公开(公告)日：2018-09-20
申请号：US15919394
申请日：2018-03-13
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia Reid
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G16B20/00 , G16B40/00
Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
-
公开(公告)号：US20170314081A1
公开(公告)日：2017-11-02
申请号：US15649274
申请日：2017-07-13
Applicant: Myriad Genetics, Inc.
Inventor： Alexander Gutin , Jerry Lanchbury , Susanne Wagner , Victor Abkevich
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/156 , G16H50/20
Abstract: Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.
-
公开(公告)号：US20170152571A1
公开(公告)日：2017-06-01
申请号：US15349866
申请日：2016-11-11
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Julia Reid
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/118 , C12Q2600/158
Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
-
公开(公告)号：US09574229B2
公开(公告)日：2017-02-21
申请号：US15010721
申请日：2016-01-29
Applicant: Myriad Genetics, Inc.
Inventor： Alexander Gutin , Kirsten Timms , Jerry Lanchbury
CPC classification number: C12Q1/6827 , C12Q1/6858 , C12Q1/6874 , C12Q1/6883 , G06F19/22 , C12Q2535/122 , C12Q2537/143
Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Abstract translation: 提供了使用核酸测序检测等位基因不平衡的方法和系统。
-
公开(公告)号：US20160355884A1
公开(公告)日：2016-12-08
申请号：US15060090
申请日：2016-03-03
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia E. Reid
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158
Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
-
Patent Agency Ranking
公开(公告)号：US20140315935A1
公开(公告)日：2014-10-23
申请号：US14186290
申请日：2014-02-21
Applicant: Myriad Genetics, Inc.
Inventor： Susanne Wagner , Steven Stone , Alexander Gutin , Julia Reid
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/118 , C12Q2600/158
Abstract: The invention provides for molecular classification of disease and, particularly, molecular markers for lung cancer prognosis and therapy selection and methods and systems of use thereof.
-
公开(公告)号：US20140170242A1
公开(公告)日：2014-06-19
申请号：US14184348
申请日：2014-02-19
Applicant: Myriad Genetics, Inc.
Inventor： Susanne Wagner , Steven Stone , Alexander Gutin , Julia Reid
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
Abstract: The invention provides for molecular classification of disease and, particularly, molecular markers for lung cancer prognosis and therapy selection and methods and systems of use thereof.
Abstract translation: 本发明提供疾病的分子分类，特别是用于肺癌预后和治疗选择的分子标志物及其使用方法和系统。
-
公开(公告)号：US11021752B2
公开(公告)日：2021-06-01
申请号：US14205965
申请日：2014-03-12
Applicant: Myriad Genetics, Inc.
Inventor： Michael Bryan Warf , Benjamin Roa , Alexander Gutin , Darl Flake
IPC: C12Q1/68 , C12P19/34 , C12Q1/6886 , G16B20/00
Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
-
公开(公告)号：US10954568B2
公开(公告)日：2021-03-23
申请号：US14632888
申请日：2015-02-26
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia E. Reid
IPC: C12Q1/6886
Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
-
公开(公告)号：US20200087737A1
公开(公告)日：2020-03-19
申请号：US16691480
申请日：2019-11-21
Applicant: MYRIAD GENETICS, INC.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6886 , C12Q1/6827 , G16B20/00
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
-
-
-
-
-
-
-
-
Search Results
68
records
(took 0.035 seconds)
